Veracyte to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Veracyte (Nasdaq: VCYT), a prominent cancer diagnostics firm, announced its participation in two upcoming investor conferences. The first is the Leerink Partners 2024 Healthcare Crossroads Conference in Austin, TX, where Veracyte will host a fireside chat on May 29th at 12:20 p.m. ET. The second is the William Blair 44th Annual Growth Stock Conference in Chicago, IL, with Veracyte presenting on June 4th at 5:40 p.m. ET. Live audio webcasts of these events will be available on Veracyte's investor relations website, with replays accessible following the live broadcasts.

Positive

• Veracyte's participation in high-profile investor conferences may boost visibility and investor interest.
• Live audio webcasts and replays of the presentations offer accessibility to a broader investor base.

Negative

• The announcement does not include new financial or clinical data, limiting its immediate impact on stock performance.
• There is no mention of upcoming product launches or business developments, which might be expected in such communications.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences.

• Leerink Partners 2024 Healthcare Crossroads Conference – Austin, TX
  Fireside Chat on May 29^th at 12:20 p.m. Eastern Time

• William Blair 44^th Annual Growth Stock Conference – Chicago, IL
  Presentation on June 4^th at 5:40 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available following the conclusion of the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515789405/en/

Investors:

Shayla Gorman

investors@veracyte.com

(619) 393-1545

Media:

Tracy Morris

media@veracyte.com

(650) 380-4413

Source: Veracyte, Inc.

FAQ

When will Veracyte present at the Leerink Partners 2024 Healthcare Crossroads Conference?

Veracyte will host a fireside chat on May 29th at 12:20 p.m. ET.

When is Veracyte scheduled to present at the William Blair 44th Annual Growth Stock Conference?

Veracyte's presentation is scheduled for June 4th at 5:40 p.m. ET.

How can I access Veracyte's presentations at upcoming investor conferences?

Live audio webcasts and replays will be available on Veracyte's investor relations website.